Company Activity* Advertising/PR/Marketing/SalesArts/EntertainmentCharityCommunicationsComputer Related ServicesComputing/IT ConstructionEducation/TrainingEnergyEngineeringFinancial Services and BankingGovernment/Local GovernmentHealthHotel/Catering/LeisureHousing/PropertyInsuranceManufacturing/ProductionPrinting/PublishingRetail and FMCGSocial Services/WelfareTelecommunicationsTransportUtilitiesAdhesives and Adhesive Products Architecture & DesignBiopharmaceuticalContract Manufacturing and Packaging Services EducationElectronic Components Engineering/Facilities/ConstructionEnvironmental-Control Products and Services GovernmentIngredients (eg Raw Materials, APIs)ManufacturingManufacturing Equipment and Software Materials OtherOutsourcing/Contract ServicesPharmaceuticalR&D, Design, and Business Services Sterilization TubingUniversity/Academia/EducationContract PackagerHousehold Paper Products ManufacturerPersonal Care Products/Cosmetic ProductsOther (please specify)Metal ConverterBeverage ManufacturerRetailersFood ManufacturerGlass ConverterTobacco ManufacturerHousehold Cleaning and Polishing Preparations ManufacturerHotel ChainFlexible Packaging ConverterPlastic ConverterPaper & Paperboard ConverterAir Navigation Service ProviderAir Transport (Airlines)Airline Industry AssociationAirport and air traffic control activitiesAirport Ground Service ContractorAirport Industry AssociationArchitects Specialising in Hotel InteriorsArchitectural Practice Specialising in Business ParksArchitectural Practice Specialising in Criminal JusticeArchitectural Practice Specialising in DefenceArchitectural Practice Specialising in EducationArchitectural Practice Specialising in Government BuildingsArchitectural Practice Specialising in Healthcare/HospitalArchitectural Practice Specialising in HotelsArchitectural Practice Specialising in IndustrialArchitectural Practice Specialising in LeisureArchitectural Practice Specialising in MasterplanningArchitectural Practice Specialising in ResidentialArchitectural Practice Specialising in RetailArchitectural Practice Specialising in Sports StadiumsArchitectural Practice Specialising in TransportArchitectural Practice Specialising in Urban Design/Commercial Building DesignAutomotive ManufacturerBuilding Contractor Specialising in Business ParksBuilding Contractor Specialising in Criminal JusticeBuilding Contractor Specialising in DefenceBuilding Contractor Specialising in EducationBuilding Contractor Specialising in Government BuildingsBuilding Contractor Specialising in HealthcareBuilding Contractor Specialising in HotelsBuilding Contractor Specialising in IndustrialBuilding Contractor Specialising in LeisureBuilding Contractor Specialising in MasterplanningBuilding Contractor Specialising in ResidentialBuilding Contractor Specialising in RetailBuilding Contractor Specialising in Sports StadiumsBuilding Contractor Specialising in TransportBuilding Contractor Specialising in Urban Design/Commercial Building DesignBusiness & Management consultancy activitiesChip Equipment ManufacturersCivil Aviation AuthoritiesComputer SoftwareConsultant to the Airport IndustryCruise Industry ConsultantsCruise LineDrilling ContractorElectronics ManufacturerEngineering/Technical ConsultantsExploration & Production of Oil & GasFinancial ServicesFinished Device Contract Manufacturing OrganisationFood, Beverage & Tobacco ManufacturerGeological/Geophysical ExplorationGovernment DepartmentsHotel Management CompanyHousehold & Personal care products manufacturerImaging CentreIn Vitro & In Vivo Diagnostic substancesIndependent HotelIndependent Oil & Gas CompanyInterior Design PracticeIn-Vitro Device ManufacturerLong-term Care FacilitiesManufacture of Finished Medical DevicesMedical Society/AssociationNational/ State owned Oil & Gas CompanyNaval ArchitectsOnboard Gambling/CasinosOnboard Gift boutiquesOnboard Retail StoresOnboard Sporting activitiesPharmaceutical ManufacturerPipeline ConstructionPipeline OperationPort Authority with Cruise FacilitiesPrivate ClinicPrivate Sector HospitalPublic Sector HospitalPublishing/MediaRetailSemiconductor ManufacturersShipyard / ShipbuilderSystems Integrators – IT RelatedSystems Integrators – Engineering/ArchitecturalTelecommunicationTravel AgencyUtilities (Electricity, Gas & Water supply)

If we are treated as a PFIC for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC for all succeeding years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable in such a situation, including the “deemed sale” election of Code Section 1298(b)(1) (which will be taxed under the adverse tax rules described above).

Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company’s board of directors. The Articles provide that the Board may from time to time declare, and cause the Company to pay, such dividends as may appear to it to be justified by the profits of the Company and that the Board has the authority to determine the time for payment of such dividends and the record date for determining the shareholders entitled to receive such dividends, provided the date is not before the date of the resolution to distribute the dividend. Declaration of dividends does not require shareholder approval.

Bode-Böger, S. M., Scalera, F. & Ignarro, L. J. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacology & therapeutics 114, 295–306 (2007).

A failure by our contract manufacturer to achieve and maintain high manufacturing standards, in accordance with applicable good manufacturing practices and other applicable regulatory requirements could result in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously harm our business. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel.

To confirm the inhibitory effects of 8-Br-ADPR on the translocation of intracellular perforin and granzyme B to the plasma membrane in response to tumor cell contact, we examined the subcellular distributions of perforin and granzyme B by Western blot. Subcellular organelles of NK cells were separated by sucrose density gradient centrifugation. Perforin and granzyme B were enriched in higher density fractions, consisting of plasma membrane from NK cells treated with plasma membrane extracts (PME) from B16F10 cells, compared to those from NK cells that had not been treated (Fig. 3d). 8-Br-ADPR inhibited the tumor-induced translocation of cytoplasmic granular proteins to the plasma membrane. These results are consistent with those in Fig. 3c, showing that intracellular perforin and granzyme B were translocated to the plasma membrane in response to tumor contact. Furthermore, we found that the B16F10 cell-induced granzyme B release from NK cells, as well as the cytolytic activity of NK cells against B16F10 cells, were inhibited by 8-Br-ADPR but not by any other inhibitors we tested (Fig. 3e and f). Taken together, these results suggest that ADPR is a key player in mediating the degranulation and cytolytic activity of NK cells.

        In 2010, the Company adopted a tax-qualified employee savings and retirement 401(k) Plan, covering all qualified employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the election of its board of directors, the Company may elect to match employee contributions. Currently, the Company makes matching contributions at a rate of 50% of the first 6% of employee contributions. The Company recorded $0.2 million of expenses related to its 401(k) match for each of the years ended December 31, 2018 and 2017.

Graeff, R. & Lee, H. C. A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity. Biochem. J. 361, 379–384 (2002).

Amateur question: would GC/MS have picked out the impurity at this level? But surely that had to have been run sometime so I can’t imagine.

Results for the two biopsy endpoints, which may currently constitute a primary endpoint for a Phase 3 trial to support an FDA marketing application, demonstrated the following: (i) significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without worsening of fibrosis (16.7% vs. 5.0%; p=0.0514); and (ii) a higher proportion of patients showed at least one-point improvement in fibrosis score without worsening of NASH in Aramchol 600mg vs. placebo (29.5% vs. 17.5%; p=0.2110).

The Company enters into contracts in the ordinary course of business with Contract Research Organizations for clinical trials and clinical supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which generally provide for termination upon 30 days notice or less, and therefore are cancelable contracts and not included in the table above. The Company has included as purchase obligations our commitments under agreements to the extent they are quantifiable and are not cancelable.

Hogman, M., Frostell, C., Arnberg, H. & Hedenstierna, G. Bleeding time prolongation and NO inhalation. Lancet. 341, 1664–1665 (1993).